Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
To assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by power Doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to therapy at 12 weeks after start of treatment
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- diagnostic test: Doppler Ultrasound
- device: SIEMENS S3000 and Verasonics Vantage 256
- drug: Vascular Endothelial Growth Factor Receptor 2 tyrosine kinase inhibitor plus immune checkpoint inhibitor
Eligibility
Inclusion Criteria:
- 18 years of age or older
- Pathology-confirmed diagnosis of metastatic RCC
- At least one tumor lesion greater than 1 cm in diameter, amenable to ultrasound
imaging
- Written informed consent.
Specific inclusion criteria:
- arm 1: planned to be treated with combination of VEGFR2 tyrosine kinase inhibitor
(TKI) plus immune checkpoint inhibitor (ICI)
- arm 2: planned to be treated with non-ICI therapy
Exclusion Criteria:
-Any comorbid condition that, in the opinion of the treating provider or the Protocol
Directors, compromises the participant's ability to participate in the study
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Christian Hoerner, PhD
650-721-3206
Not Recruiting
Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.
Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.
